An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis
Phase of Trial: Phase IV
Latest Information Update: 25 Aug 2016
At a glance
- Drugs Ivacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 22 Aug 2016 Status changed from active, no longer recruiting to completed.
- 25 Jul 2014 Planned number of patients changed from 80 to 95 as reported by ClinicalTrials.gov record.
- 25 Jul 2014 Planned End Date changed from 1 May 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov record.